Aankondiging • Mar 03
Tristel plc Recommends Interim Dividend for the Year Ended 30 June 2026, Payable on 9 April 2026 The Board of Tristel plc recommended an interim dividend of 5.68 pence (2024: 5.68 pence) for the year ended 30 June 2026 to be paid on 9 April 2026. The associated ex-dividend date will be 19 March 2026 with a record date of 20 March 2026. Aankondiging • Feb 06
Tristel plc to Report First Half, 2026 Results on Mar 02, 2026 Tristel plc announced that they will report first half, 2026 results on Mar 02, 2026 Aankondiging • Jan 22
Tristel plc Announces Resignation of Matt Sassone as Chief Executive Officer Tristel plc announced that Matt Sassone, Chief Executive Officer, has confirmed to the Board his decision to resign to take up a worldwide President role with a large US multinational, leading a significant global business. Matt will actively continue in post until the end of the financial year and has fully committed to continue leading the business through this period. The Board has already commenced the process to appoint a new CEO and is confident that there is sufficient management depth in the business to ensure that trading will not be impacted during the transition. Aankondiging • Nov 24
Tristel plc Updates US Guidelines for High Level Disinfection Tristel plc expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD"). Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market. Aankondiging • Nov 18
Tristel plc, Annual General Meeting, Dec 11, 2025 Tristel plc, Annual General Meeting, Dec 11, 2025. Location: the companys registered office, unit 1b lynx business park, fordham road snailwell, newmarket, cambridgeshire, cb8 7ny, United Kingdom Aankondiging • Sep 27
Tristel plc Announces the Launch of Its New Ultrasound Probe Decontamination Product Tristel plc announced the launch of its new ultrasound probe decontamination product, Tristel VISICLEAN™?, the first detergent of its kind with colour technology, enabling visible coverage and confirmation of high level disinfection. Tristel VISICLEANtm is deployed on the ultrasound probe, dying it pink, and when exposed to Tristel ClO2 via Tristel DUO ULT™?, the pink dye disappears, visibly verifying that the probe has been high level disinfected. Tristel VISICLE AN™? is now available within the VISI Combination Pack, a convenient, all-in-one solution for ultrasound probe decontamination. Effective high-level disinfection begins with cleaning, which eliminates organic matter and reduces microbes to ensure proper sterilisation. This is performed manually and must be done each time. Tristel VISICLEan™? is the only cleaning solution with visible verification, ensuring full auditability and compliance with protocols. Tristel VISICLEAC™?, DUO ULT™? and DRY WIPEStm, the products within the VISI Combination pack includes the Company's new product, Tristel VISVEAN™?, along with two pre-existing products, Tristel DUO U LT™? & Tristel DRY WIPESt m. Together, these products enable clinicians to perform manual decontamination procedures with confidence, precision, and audit-ready traceability via Tristel's 3T™? digital platform. VISI Combination Packs are now available to healthcare providers across the UK and are being launched globally on a phased basis, as and when the Company secures the necessary local regulatory clearances. Tristel's proprietary chlorine dioxide chemistry is globally trusted for its broad-spectrum efficacy and resistance-proof mechanism. With over 30 years of experience in high-level disinfection, Tristel continues to remain at the forefront of infection prevention. Aankondiging • Sep 16
Tristel plc to Report Fiscal Year 2025 Results on Oct 13, 2025 Tristel plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Oct 13, 2025 Aankondiging • May 12
Tristel plc Announces FDA Clearance for Tristel OPH Ophthalmic High-Level Disinfectant Now Approved for Immediate Sale in the US Tristel plc announced that the U S Food and Drug Administration ("FDA") has completed its review of the Company's 510(k) filing for Tristel OPH, and has granted its clearance for immediate sale. Tristel OPH is a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters, lenses, retinal imaging probes, A-scan and B-scan biometry probes that make contact with the cornea. With c.16 million ophthalmic procedures taking place every year in North America, the Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Until now, the only FDA-cleared HLD method available for ophthalmic devices involves soaking in an open tray. This method is slow, given the long contact times required to be effective, and has as a result proven to be impractical to implement at point of care. In addition, the use of chemicals, such as sodium hypochlorite or hydrogen peroxide in an open tray, leads to occupational health concerns and may require costly implementation of ventilation. Prolonged exposure in a chemical soak can also lead to device damage. To address the problems, some clinics have turned to costly single-use devices, for which there is not always an option, while others have compromised by using low-level disinfectants options, such as alcohol wipes. In comparison, Tristel OPH has a short contact time of two minutes, is compatible with all widely used ophthalmic medical devices, is easily used at the point of care and is instantly deployable. The Company has already established local US manufacturing with its partner Parker Laboratories, and numerous leading eye institutes in the US have already approached Tristel to become early adopters in anticipation of FDA clearance for Tristel OPH. Tristel OPH directly addresses a long-standing unmet need in ophthalmic device reprocessing-offering a fast, safe and practical alternative to the outdated and often hazardous methods still in use. Aankondiging • Apr 11
Tristel plc Submits Additional Information to the FDA for Tristel OPH Tristel plc confirmed it has submitted the additional information requested by the U.S. Food and Drug Administration (FDA) for Tristel OPH, a high-level disinfectant foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The Company now expects a decision from the FDA by the end of June 2025. As announced in September 2024, the 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a high-level disinfectants labelled for use on endocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. With c.16 million ultrasound procedures taking place every year in North America, the Board continues to believe that FDA clearance has the potential to transform ophthalmic disinfection practice in the region. Tristel OPH addresses operational inefficiencies arising from complex and time-consuming decontamination practice. In addition, very few semi-critical ophthalmic devices are subject to effective high-level disinfection in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be wet in sodium hypochlorite (Milton) or hydrogen peroxide in open trays with long contacts times. Aankondiging • Feb 24
Tristel plc Recommends an Interim Dividend for the Year Ended 30 June 2025, Payable on 11 April 2025 The Board of Tristel plc is recommending an interim dividend of 5.68 pence for the year ended 30 June 2025 (2023: 5.24 pence) to be paid on 11 April 2025. The associated ex-dividend date will be 20 March 2025 with a record date of 21 March 2025. Aankondiging • Dec 16
Tristel plc to Report First Half, 2025 Results on Feb 24, 2025 Tristel plc announced that they will report first half, 2025 results on Feb 24, 2025 Aankondiging • Nov 23
Tristel plc, Annual General Meeting, Dec 16, 2024 Tristel plc, Annual General Meeting, Dec 16, 2024. Location: the companys headquarters, unit 1b lynx business park, fordham road, newmarket, cambridgeshire, cb8 7ny, snailwell United Kingdom Aankondiging • Oct 21
Tristel plc Recommends Final Dividend, Payable on 20 December 2024 The Board of Tristel plc is recommending a final dividend of 8.28 pence (2023: 7.88 pence). Combined with the interim dividend of 5.24 pence, the total dividend pay-out for the year will be 13.52 pence per share, this is an increase of 29% on last year's total dividend pay-out of 10.50 pence. Going forward the Board's intention is to increase the dividend annually in line with the year's increase in EPS, committing to minimum dividend growth of 5%. This final dividend will be paid on 20 December 2024, to shareholders on the register on 29 November 2024, the associated ex-dividend date is 28 November 2024. Aankondiging • Oct 01
Tristel plc to Report Fiscal Year 2024 Results on Oct 21, 2024 Tristel plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Oct 21, 2024 Aankondiging • Sep 12
Tristel plc Announces Filing of Premarket Notification 510(K) with the US Food and Drug Administration for Tristel OPH Tristel plc announced that it has filed a Premarket Notification 510(k) with the US Food and Drug Administration ("FDA") for Tristel OPH, a high-level disinfectant ("HLD") foam for use on ophthalmic medical devices, including re-usable tonometers, pachymeters and lenses that make contact with the cornea. The 510(k) filing for Tristel OPH will use Tristel ULT as its predicate device. Tristel ULT, a HLD labelled for use onendocavity ultrasound probes and skin surface transducers, was cleared for sale in the US by the FDA in June 2023, following the Company's De Novo submission. The Board believes that FDA clearance has the potential to transform ophthalmic disinfection practice in North America. According to the Spaulding classification1, semi-critical devices require reprocessing with a HLD because they touch mucous membranes or non-intact skin, which is the case for nearly all ophthalmic devices. Very few semi-critical ophthalmic devices are subjected to an effective HLD in the US. Low-level disinfectant options such as alcohol wipes are used as an alternative, or devices may be soaked in sodium hypochlorite (bleach) or hydrogen peroxide in open trays with long contacts times. Aankondiging • Sep 02
Tristel plc Announces Bart Leemans Will Step Down from Position of Executive Director Tristel plc announced that Bart Leemans will step down from the Tristel Board as an Executive Director. He will remain with the business and continue to focus his efforts on the French market in his capacity as Managing Director, Tristel SAS. There are no current plans to replace Bart on the Tristel Board. Bart was appointed in November 2018 following Tristel's acquisition of his business, the Ecomed Group, the Company's then distributor in Belgium, the Netherlands and France. Aankondiging • May 09
Tristel plc Announces the Publication of A White Paper Simplifying High-Level Disinfection for Urological Procedures Tristel plc welcomes the publication of a white paper ‘ Simplifying High-Level Disinfection for Urological Procedures: A Case Study’ at the American Urological Association (‘AUA’) 2024 conference, the gathering of urologists in the world. In June 2023 the Food and Drug Administration (‘FDA’) created a new category of Class II medical device disinfectants titled ‘foam or gel chemical sterilant/high-level disinfectant’ under which De Novo clearance for Tristeltm ULT was granted. As referenced within Dr. Allaway's study, Tristeltm ULT is recognised as a high level disinfectant (‘HLD’) and is effective against pathogens ranging from Human papillomavirus (‘HPV’) type 16 and type 18 to Mycobacterium terrae. Tristeltm ULT helps to address numerous bottlenecks that can impact workflow in a busy urology practice. One of the most time-consuming tasks is reprocessing medical devices between procedures. Chemical soaking and misting methods of HLD can damage probes and require complex workflows limiting the number of procedures clinicians can perform during a typical patient list. Aankondiging • Jan 23
Tristel plc Announces Canadian Regulatory Approval for Tristel Ult as a high-level disinfectant Tristel plc announced that Health Canada has approved Tristel ULT as a Class II Medical Device for endocavity ultrasound probes and skin surface transducers. The timing of this regulatory approval comes well ahead of the Company's original aim for gaining approval before the end of H1 Fiscal Year 2025 and allows commercial launch during fiscal 2024. Health Canada approval, alongside approval from the US Food and Drug Administration received in June 2023, means that Tristel ULT can now be manufactured and sold throughout the whole of North America by Tristel's commercial partner Parker Laboratories Inc. as a high-level disinfectant for ultrasound instruments. Parker completed its first production run of Tristel ULT in October 2023 and is actively introducing the product to its United States distribution network. This activity will now be extended to the Canadian market. The first hospital users in the United States are trialling and purchasing the product. Tristel will provide a more detailed update in its interim results on 26 February 2024. Tristel is preparing its dossier for Tristel OPH, a high-level disinfectant For use on ophthalmic instruments, for submission to the FDA and has requested a pre-submission meeting with the agency. The review meeting date is scheduled for early March 2024. The Company anticipates completing its submission seeking 510(k) approval in the summer and receiving FDA approval by the end of the year. Tristel OPH was approved by Health Canada in June 2021. Tristel OPH were launched into the Canadian ophthalmic market as a high-level disinfectants for ophthalmic instruments including re-usable tonometers and lenses that contact the cornea during the Company's last financial year. The product is being distributed throughout the country by Innova Medical Ophthalmics Inc., Toronto, a subsidiary of Advancing Eyecare, Jacksonville, Florida. Tristel OPH is being used by public health authorities in all the major Canadian provinces. Aankondiging • Sep 12
Tristel plc to Report Fiscal Year 2023 Results on Oct 16, 2023 Tristel plc announced that they will report fiscal year 2023 results on Oct 16, 2023 Aankondiging • Sep 05
Tristel plc Announces Regulatory Approval for EPA, Canada and South Korea Tristel plc announced that it has received three significant regulatory approvals. United States Environmental Protection Agency (EPA) Tristel received its first approval from the EPA for its foam-based disinfectant for surfaces in April 2018. The company successfully enhanced the performance claims of the product with a second approval in January 2019 and then registered the product in three States before curtailing the nationwide registration programme until a third submission could be made to bolster further the competitive positioning of the product. This submission was made in October 2020 and the company have now received the third approval for Jet. This expands the product's efficacy claims to include mycobacteria, and all efficacy claims are within a contact time of two minutes. The company expects to complete State-by-State registration by the end of June 2022, including California where company existing registration will require amendment, which can be a lengthy process. 
